Immunogenicity and Safety Study of GlaxoSmithKline Biological's Live Attenuated Measles Mumps Rubella Varicella Vaccine (PriorixTetra™) When Co-administered With Conjugated Meningococcal C Vaccine (Meningitec®, Nuron Biotechs' Vaccine) in Healthy Children

GlaxoSmithKline1 site in 1 country716 target enrollmentFebruary 6, 2012

ConditionsRubella Varicella Measles Mumps

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Rubella
Sponsor: GlaxoSmithKline
Enrollment: 716
Locations: 1
Primary Endpoint: Number of Seroconverted Subjects for Measles, Mumps, Rubella, and Varicella Virus
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' investigational measles, mumps, rubella and varicella (MMRV) vaccine (GSK208136, PriorixTetra™) when co-administered along with conjugated Meningococcal C (MenC) vaccine (Meningitec®, Nuron Biotechs' Vaccine) in healthy children.

Registry

clinicaltrials.gov

Start Date

February 6, 2012

End Date

March 31, 2014

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

GlaxoSmithKline

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects who the investigator believes that parent(s)/Legally Acceptable Representatives (LAR) can and will comply with the requirements of the protocol.
•A male or female between, and including, 13 and 15 months of age at the time of the first vaccination.
•Written informed consent obtained from the parent(s)/ LAR of the subject.
•Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria

•Child in care.
•Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the dose of study vaccine, or planned use during the study period.
•Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
•Planned administration/ administration of a vaccine not foreseen by the study protocol starting 30 days prior to the study vaccination/s and ending 42 days after the vaccination/s (at Visit 2), with the exception of inactivated influenza (flu) vaccine, which may be given at any time during the study, including the day of study vaccination/s.
•Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
•Previous vaccination against measles, mumps, rubella, varicella/ herpes zoster and/or N. meningitidis serogroup C.
•History of measles, mumps, rubella, varicella and/or N. meningitidis serogroup C diseases.
•Known exposure to measles, mumps, rubella and or varicella starting 30 days prior to enrolment.
•Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
•Family history of congenital or hereditary immunodeficiency.

Outcomes

Primary Outcomes

Number of Seroconverted Subjects for Measles, Mumps, Rubella, and Varicella Virus

Time Frame: At 42 days after vaccination

Seroconversion was defined as the appearance of antibodies (i.e. concentration/titer ≥ the cut-off value) in the serum of subjects seronegative before vaccination. The cut-off values for serocoversion were 150 mIU/mL, 231 U/mL, 4 IU/mL and 25 mIU/mL for measles, mumps, rubella and varicella, respectively.

Number of Seroprotected Subjects for rSBA-MenC Antibodies

Time Frame: At 42 days after vaccination

Seroprotection was defined as the appearance of rSBA-MenC antibody titer ≥ 1:8.

Secondary Outcomes

Antibody Titers Against Measles, Mumps, Rubella and Varicella Viruses(At Day 42 after vaccination)
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms(During the 4-day (Days 0-3) post-vaccination period)
Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms(During the 43-day (Days 0-42) post-vaccination period)
Number of Subjects Reporting Any, Localised and Generalised Rashes(Within the 43-day (Days 0-42) post-vaccination period)
Number of Subjects Reporting Fever Per Half Degree(During the 43-day (Days 0-42) post-vaccination period)
Number of Subjects With Any Unsolicited Adverse Events (AEs)(Within 43 days (Days 0-42) after each vaccination)
Number of Subjects With Serious Adverse Events (SAEs)(Throughout study period (from Day 0 to approximately Month 4))